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Abstract 
 
Introduction: The appropriate management of patients with osteoporosis and the rational use of 
antibiotics are growing concerns in Pakistan. The first step to improve patient care is to 
understand current prescribing patterns and the rationale behind these patterns. Aim: To assesses 
utilisation patterns, prescribing behaviour and the potential rationale among a range of medicines 
including bisphosphonates and antibiotics. Subsequently, use the findings to suggest potential 
future policies for all key stakeholders to improve patient care in the future. Methodology: A 
questionnaire based, cross-sectional study in both private and public health care facilities in 
Pakistan, conducted between January 2011 and December 2012, involving 438 physicians 
and15824 prescriptions. The second study involved 9984 outpatient prescriptions, 127 in-patient 
cases and over 100 prescribers and dispensers. Results: There was adequate history taking and 
examinations in approximately half of the physicians surveyed, with prescribing typically taking 
into account issues such as disease severity (84% of respondents) and the socioeconomic status 
of patients (53%). Prescribing of bisphosphonates was common certainly compared to medicines 
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to treat cardiovascular diseases and diabetes. However, there are concerns with the low use of 
generics, high rate of antibiotic prescribing, variable availability of medicines, medical 
representatives being a key source of information on medicines and typically a limited number of 
formularies. Discussion: There are considerable opportunities to improve the rational use of 
medicines in Pakistan including physician education, prescribing guidance and formularies. In 
addition, educating patients and physicians concerning antibiotics. These should be co-ordinated 
among key stakeholder groups. There is also a need to ensure low prices for generics and 
enhance their utilisation. 
 
Keywords: Antibiotics, bisphosphonates, generics, influencing prescribing, Pakistan.  
 
Introduction 
 
The evaluation and assessment of health care quality is receiving worldwide attention (1, 2), with 
medicines playing an important role to improve the health of patients (3, 4).  However in some 
countries, the costs of medicines can be up to 60% of total healthcare expenditure (5). This 
includes Pakistan where expenditure on pharmaceuticals accounts for 47% of total healthcare 
expenditure  (6). Private healthcare currently accounts for over two thirds of total healthcare 
expenditure (7, 8) and over 70% of the total expenditure on pharmaceuticals (6). However, the 
limited availability of even essential medicines including generics in the public sector forces 
patients to purchase their medicines in the private sector, where there is a proliferation of 
originators (brand named medicines) rather than generics (9). This enhances out-of-pocket 
payments. As a result, up to 64% of total healthcare expenditure is currently borne by households 
in Pakistan, with medicines accounting for 43% of household expenditure on health (9).   
 
Pharmaceutical expenditure will continue rising across countries unless addressed, driven by 
well known factors including ageing populations, rising patient expectations and the continued 
launch of new premium priced technologies (8, 10-13). Potential ways instigated by health 
authorities to address this include encouraging the prescribing of low-cost generics, especially 
where  generics are priced at 2% to 10% of pre-patent loss prices such as the Netherlands, 
Sweden and the United Kingdom (14-16). However, this can be a challenge in countries where 
there are limited availability of generics, a tendency for physicians to prescribe originators 
(Brand name products) and where prices of generics can be high. This includes Pakistan. 
Currently there is limited prescribing of generics particularly in the private sector, e.g. over 90% 
of patients in the private sector typically request originators (Personal communication S Hussain) 
and prices of generics vary between 0.2 to 7.02 times that of international reference prices 
among a basket of products (8, 9). However, generic prices tend to be lower in the public sector 
when procured centrally by provinces, i.e. an average of 0.74 of the international reference price 
among a basket of products (7). It was estimated in 2010 that even with this range in the pricing 
of generics, an average of 51% of pharmaceutical costs could be saved among 9 medicines 
studied with their increased use (17). 
 
Enhancing adherence to the medicines prescribed will help to improve outcomes and reduce long 
term costs as well as increase physician familiarity with the medicines they prescribe. This can 
be achieved through the use of formularies and prescribing guidance (18, 19), thereby reducing 
adverse drug reactions (ADRs) and drug interactions and their associated costs (20-22).   
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The unnecessary and inappropriate use of antibiotics is also an increasing concern among health 
authorities worldwide as this can increase antibiotic resistance and associated costs (23-26).  
Increasing antibiotic resistance will reduce physicians' abilities to treat future infections due to 
the lack of therapeutic options, adding to medicine and other costs. These concerns have resulted 
in activities across countries involving all key stakeholder groups to reduce inappropriate 
antibiotic prescribing in both hospital and ambulatory care (27-31). The prescribing of antibiotics 
has also been high in Pakistan, i.e. 62% of prescriptions in the private sector include antibiotics 
and 54% in the public sector (9, 32), with currently few  measures to address this. The improper 
use of medicines including antibiotics reduces the ability of the authorities to manage priority 
disease areas within available resources (33-38) as well as adversely affect the treatment of 
future infections.  
 
There is an essential medicines list in Pakistan (Essential Drug List ± EDL) which contains 335 
medicines (9). However, there are concerns with physician adherence to the EDL with currently 
few demand-side measures to encourage adherence, over 1100 to 1200 registered molecules and 
over 50,000 registered drug products currently in Pakistan, appreciable influence of 
pharmaceutical companies, and variable availability of generic medicines (9, 39). There are also 
Standard Treatment Guidelines (STGs) for a number of diseases. However, again there are few 
demand-side measures from the authorities to enhance adherence to STGs (Personal 
Communication S Hussain). This compares with the Stockholm Metropolitan Healthcare Region 
in Sweden, where there has been a tradition of selecting evidence-based medicines for common 
diseases as well as providing treatment guidance (40). Since 2000, approximately 200 medicines 
have been selected to treat the majority of common diseases in ambulatory care (18), akin to an 
essential medicines list (41). Respected specialists, working jointly with clinical 
pharmacologists, pharmacists and general practitioners in over 20 expert groups, suggest which 
medicines should be selected and included in the list (18, 40). The recommendations 
subsequently form the µ:LVH/LVW¶IRUWKDW\HDU, which is subsequently widely communicated and 
disseminated (18, 19). There is currently high adherence WRWKHµ:LVH/LVW¶UHFRPPHQGDWLRQVat 
87% of all prescriptions (18). High physician adherence is enhanced by the use of robust criteria 
for medicine selection and the use of respected personnel (18, 40). Published studies have shown 
that care is not compromised with increased DGKHUHQFHWRWKHµ:LVH/LVW¶UHFRPPHQGDWLRQV; 
however, costs are reduced (40, 42, 43).  As a result, endorsing this approach in Stockholm.  
 
Enhancing adherence rates to medicines is also important as rates are currently low in patients 
with chronic asymptomatic diseases (44-46). Potential measures could include quality of care 
initiatives with this information increasingly being demanded by policy makers, healthcare 
professionals and the general public (2, 47). Standard setting and assessment of the subsequent 
quality of care through performance review should be part of everyday clinical practice, although 
it is recognised that healthcare professionals should not be overloaded (2, 48, 49). However, this 
is a challenge where there are issues with medicine availability, high out-of-pocket payments, 
limited adherence to treatment guidelines and no requirements for hospitals to organise and 
develop Drug and Therapeutic Committees (DTCs). All of which are issues in Pakistan (6, 9).  
 
Osteoporosis is a systemic skeletal illness illustrated by low Bone Mass Density (BMD) and 
micro architectural weakening of bone tissue. It is more common amongst people older than 50, 
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with an estimated prevalence of up to one in four women and one in eight men (50-53), and is 
associated with considerable economic burden (54). Currently, it is estimated approximately 75 
million people worldwide are affected by osteoporosis (53). In the US, more than 10 million 
people currently have osteoporosis (55) and in Europe, twenty-two million women and 5.5 
million men are estimated to have osteoporosis (53). This leads to more than 8.9 million 
fractures annually worldwide (53). Overall, one in two Caucasian women and one in five men 
will experience an osteoporosis-related fracture at some point in their lifetimes (55).  The 
prevalence of osteoporosis in Pakistan is also high (56, 57). Estimates suggest 97% of women 
aged 75-84 years and 55% of women aged 45-54 years are prone to osteoporosis (58). 
 
Osteoporosis is responsible for the third highest number of disability life years in Europe after 
ischaemic heart disease and chronic obstructive pulmonary disease (COPD) (53). The acute and 
long-term medical care costs linked with osteoporotic fractures were estimated at US$17 billion 
in in the United States alone in 2005 (55, 59). In addition to direct medical costs, osteoporosis 
also leads to considerable indirect costs, chiefly due to associated disabilities and early death (53, 
60). As a result, improved management of patients with osteoporosis should be a priority among 
the authorities in Pakistan. 
 
Bisphosphonates are currently recommended as first-line treatment for patients with osteoporosis 
following a fracture to reduce the risk of subsequent fractures (53, 55, 61-64). They are potent 
inhibitors of bone resorption and are widely used in the treatment of osteoporosis and other 
diseases that cause bone mass loss (53, 65). Despite the demonstrated clinical benefits of 
bisphosphonates (64), adherence can be poor leading to a higher risk of fractures (51, 61, 65-69). 
Overall, poor adherence reduces by over 50% the potential benefits of medicines to treat 
osteoporosis (70).  The principal reasons for non-adherence include troublesome side effects 
such as GI side-effects, out-of-pocket expenses and practical difficulties with their 
administration, which includes inconvenient dosing regimens (51, 64, 68, 69, 71). GI side-effects 
are often treated with proton pump inhibitors (PPIs) (72, 73). However, there are increasing 
concerns with the long-term use of PPIs, including concomitant use with bisphosphonates, and 
the increasing risk of fractures (73-76).  
 
A first step to improving the rational use of medicines in Pakistan, especially in high priority 
disease areas including osteoporosis and infections, is to understand current prescribing patterns 
and the rationale behind these.  Subsequently, use the findings to guide future policy initiatives. 
Consequently, the principal objective of this study is to assesses current medicine utilisation 
patterns including originators versus generics, prescribing behaviour and the potential rationale 
among a range of medicines including bisphosphonates and antibiotics using indicators and 
methods described by World Health Organisation (WHO) (77-79).  
 
5 
 
Methodology 
 
Principal study 
 
A questionnaire based, cross-sectional study was conducted in both private and public health 
care facilities among five large cities of two Provinces of Pakistan (Punjab and Khyber 
Pakhtonkhwe ± KPK) from January 2011 to December 2012. These cities and provinces were 
chosen as they represent approximately half the population of Pakistan. The survey methodology 
was adapted based on developed WHO guidance (78, 79). To date, it has been implemented in 
over 13 developing countries (77, 79).  The questionnaire was based on indicators for appropriate 
drug prescribing. The practitioners were informed that the data was being collected for academic 
purposes from the hospitals or private practice settings and the purpose of the study was not to 
affect changes in their prescribing behaviour. The principal emphasis of this study was on the 
management of osteoporosis. However, all medicines prescribed were incorporated into the 
study, including those to treat hypertension, hyperlipidaemia and diabetes, to provide additional 
background to the study. 
 
To enhance the robustness of the findings, the survey instruments were developed and pre- tested 
in another district; however, this data was not included in this study. Data was collected on 
prescription practices, drug availability at each facility, as well as the attributes and 
characteristics of the prescribers. Pharmacists and a final year Pharmacy students undertook the 
surveys with each member trained in administering survey instruments. In case it was not 
possible to collect adequate prescription histories during the first visit, the same health facilities 
were re-visited until the required sample size of prescriptions was achieve. The sampling unit 
was the patient prescriber encounter (P-P encounter). The sample size was estimated using 
quality of the prescription as the outcome variable. Studies on GPs from Karachi (80) had shown 
that in cases of diarrhoea in children, the quality of prescription was inadequate in over 50% of 
P-P encounters. Using this figure as an indicator of the overall quality of prescription with a 
precision level of ±5.0% at 95% confidence level, the estimated sample size was 5,000 P-P 
encounters. Data Processing and Analysis were undertaken through the Statistical Package for 
the Social Sciences (SPSS-16) and outcome (or dependent) variables, i.e. the quality of 
prescription and the quality of consultation were computed. Overall, data from 438 physicians 
was collected involving a total of 15824 prescriptions. 
 
The quality of the prescription, i.e. whether adequate or inadequate, was assessed by a team of 
interviewers for each patient-provider encounter, especially trained for this purpose. This 
assessment was based on the likely diagnosis and the standard treatment for the identified health 
problem and the treatment prescribed i.e. drug(s) group, the mode of administration (type), 
dosage and the duration of treatment given to the patient. The quality of consultation was also 
computed based on the quality of the prescription (above), the adequacy of history taking, 
UHOHYDQFHRISK\VLFDOH[DPLQDWLRQFRQVXOWDWLRQWLPHGLVSHQVLQJWLPHDQGSDWLHQW¶VVDWLVIDFWLRQ
with their consultation. In addition, patients were stratified by their income (Pak Rs), self 
reported health status (3 categories ± Good, Fair or Poor) and whether they have had a fracture ± 
Yes or No.  
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Finally, physicians were also questioned on factors that influenced their prescribing. The themes 
were subsequently collated into nine categories including the socio-economic status of the 
patient, severity of the disease, availability of drugs at the facility, and the age of the patient.  
 
The study was approved by the Ethics committee of the Department of Pharmacy and Board of 
Studies of Sargodha University, Sargodha, Pakistan. 
 
Secondary study 
 
A retrospective audit of in- and out-patient prescriptions was carried out in the same two 
Provinces to evaluate the indicators of drug use pattern including for instance the average 
number of drugs prescribed per encounter (ANDPE), the average number of antibiotics 
prescribed per encounter (ANAPE), % encounter with antibiotics (PEA) and % of antibiotic 
prescriptions based on microbial sensitivity test results (MCST).  
 
A "knowledge, attitude and practice" (KAP) questionnaire survey of hospital prescribers and 
dispensers was also performed in the two Provinces. Indicators of prescribing and dispensing 
quality incorporated into the questionnaire included: (i) sources of drug/prescribing information, 
(ii) availability and use of the hospital formulary, (iii) knowledge of the prescribing process (4 
steps) and (iv) the adequacy of the drug supply management system from their perspective. 
 
A total of 9984 outpatient prescriptions and 127 in-patient case notes were audited. The total 
number of prescribers and dispensers surveyed were 88 and 13 respectively. 
 
The study was also approved by the Ethics committee of the Department of Pharmacy and Board 
of Studies of Sargodha University, Sargodha, Pakistan. 
 
Results 
 
Principal study 
 
Table 1 gives the breakdown of the patients receiving prescriptions by gender, age, and income. 
The socioeconomic parameters of the patients, their self-reported health and history of the 
fracture are given in Table 2. There are significant differences between Punjab and KPK in a 
number of parameters including age, income, health (fair and poor) as well as history of 
fractures.   
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Table 1: Age/ gender distribution of the patients 
 
Age Group (Yrs) No. of Patients Punjab KPK p value 
Less than 30 248 (1.56%) 202 (2.18%) 46 (0.70%) <0.001 
30-40 2028 (12.82%) 1168 (12.61%) 860 (13.10%) <0.001 
41-50 3006 (18.99%) 1690 (18.25%) 1316 (20.05%) <0.001 
51-60 4012 (25.35%) 2379 (25.69%) 1633 (24.88%) <0.001 
61-70 3888 (24.57%) 2398 (25.89%) 1490 (22.70%) <0.001 
Above 71 1576 (9.96%) 922 (9.96%) 654 (9.96%) <0.001 
Age not mentioned 1066 (6.73%) 502 (5.42%) 564 (8.59%) Ns 
Total Male patients 8044 (51%) 4638 (51.4%) 3406 (51.5%)  
Total Female patients 7780(49%) 4593 (49.6%) 3187 (48.5%)  
Total patients 15824 9261 6563 <0.001 
 
Table 2: Socioeconomic parameters of the patients 
 
       Income (Pak Rs) 
   Total Punjab KPK p value 
<10000 4222 2284 1938 <0.05 
20000 8004 4448 3556 <0.01 
50000 1098 729 349 <0.001 
100000 1434 1122 312 <0.001 
Above 100000 1066 628 438 <0.001 
      Self-reported health  
Good 5438 2863 2575 Ns 
Fair 4480 3144 1336 <0.001 
Poor 5906 3224 2652 <0.01 
History of fracture  
Yes 1289 942 347 <0.001 
No 14535 8289 6246 <0.001 
Gender  
Male  8044 
(51%) 
4638 
(51.4%) 
3406 
(51.5%) 
 
Female 7780 
(49%) 
4593 
(49.6%) 
3187 
(48.5%) 
 
 
Table 3 contains details of the consultation indicators across the two provinces, i.e. Punjab and 
Khyber Pakhtonkhwa (KPK). This includes adequate history taken, relevant physical 
examination, diagnosis informed to the patient, the number of drugs prescribed by public or 
private sector as well as the average number of drugs prescribed. Again, there are significant 
differences between the two provinces in a number of the parameters including informing 
patients and requesting laboratory tests.  
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Table 3: Consultation Indicators  
 
Indicators No. of Prescriptions 
n = 15824 
Punjab KPK p value 
Adequate history 
taken 
9060 
(50.63%) 
6188 2872 <0.001 
Relevant physical 
examination done 
8238 
(49.68%) 
5320 2918 <0.001 
Diagnosis informed 
to patient 
10590 
(59.18%) 
7844 2746 <0.001 
Diagnosis written on 
the prescription 
11875 
(75.78%) 
7020 4855 <0.001 
Lab tests ordered 7340 
(41.02%) 
3914 3426 Ns 
Lab tests required 5382 
(30.85%) 
2884 2498 <0.05 
No. of drugs 
prescribed 
77538 42424 35114 <0.01 
No. of drugs 
prescribed by Brand 
names 
59880 
(70.67%) 
33155 26725 <0.01 
No. of generics 
prescribed 
17658 
(29.32%) 
9244 8414 Ns 
No. of drugs 
prescribed by Public 
Sector physicians 
31586 16543 15043 Ns 
No. of drugs 
prescribed by Private 
Sector physicians 
45952 26262 19690 <0.001 
Average no. of drugs 
prescribed 
5.11    
Average no. of drugs 
prescribed in  Punjab 
4.90    
Average no. of drugs 
prescribed in KPK 
5.32    
 
The therapeutic classes of drugs prescribed among all drugs prescribed are included in Table 4, 
which includes bisphosphonates, vitamins and calcium. Again there are significant differences 
between the two provinces in some of the drugs prescribed.   
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Table 4: Categories of Drugs Prescribed (Total population) 
 
Therapeutic 
class of Drugs 
Total no. of Drugs Punjab KPK p-value 
Bisphosphonates 12672 (16.34%) 7255 5417 <0.001 
NSAIDs 8360 (10.8%) 5342 3018 <0.001 
Vitamin D3 8248 (10.6%) 5586 2662 <0.001 
General Vitamins 
and calcium  
5060 (6.5%) 2580 2480 Ns 
PPIs 6382 (8.2%) 3466 2916 <0.05 
Antidiabetic 7280 (9.4%) 3955 3325 <0.05 
Antihypertensives 7734 (10%) 4080 3656 Ns 
Lipid lowering 
Drugs 
7820 (10.1%) 4490 3330 <0.001 
Steroids 4382 (5.6%) 1886 2496 <0.001 
Injectables 3582 (4.6%) 1472 2110 <0.001 
Tranquilizers or 
sedatives 
3506 (4.5%) 1431 2075 <0.001 
Others 5038 (6.5%) 2856 2182 <0.001 
Total 77538 (100%) 44424 33139  
  
Table 5 contains data on the  cost of drugs prescribed, broken into 6 groups to aid comparative 
purposes. These are 0 to 150 (Pak Rs), 151-250, 251 ± 350, 351 ± 450, 451 ± 550, and 551 or 
above (Table 5). Again, there are significant differences between the two provinces.  
 
Table 5: Cost analysis ± total population 
 
Cost (Rs) Number of 
prescriptions 
& (%) 
Punjab KPK p value 
0-150 6684 (42.2) 3660 3024 <0.01 
151-250 3674 (23.2) 2186 1488 <0.001 
251-350 2018 (12.8) 1328 690 <0.001 
351-450 840 (5.3) 524 316 <0.001 
451-550 1280 (8.1) 756 524 <0.001 
Above  551 1328 (8.4) 777 551 <0.001 
 
Table 6 refers to the factors that influenced physician prescribing among the sampled physicians. 
Again, there were significant differences between the two provinces. However, formularies or 
prescribing guidance was not available at most of the facilities. 
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Table 6: Prioritization of factors that influence prescription among all respondents 
(No. of responses = 438) 
 
Influencing Factor Responses % 
of Punjab 
Response 
% of KPK 
p value 
Socio-economic status of the patient 53% 
35% <0.001 
Previous experience of treating 
patients 33% 
24% <0.001 
Severity of disease 84% 
78% Ns 
Patient demand for specific drugs 38% 
21% <0.001 
Availability of drugs at facility 53% 
34% <0.001 
Placebo effect of drugs 7% 
8.5% <0.01 
Age of the patient 74% 
54% <0.001 
Concern of losing patients to others 
practitioners 34% 
56% <0.001 
Others 12% 
9% <0.001 
 
Finally, Table 7 describes the current sources of information used by physicians when making 
their prescribing choices. This principally centres on medical representatives, with again 
significant differences between the two provinces.  
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Table 7: Source of Information on medicines (n = 438) 
  
Source 
Percentage% 
Practitioners 
of Punjab 
Percentage% 
Practitioners 
of KPK 
p value 
Medical Representative 68% 
 
86% <0.01 
Textbooks on pharmacology 26% 
 
14% <0.001 
 
Therapeutic Indices 12.0% 
 
18% <0.001 
 
Charts and Guidelines 28% 
 
12% <0.001 
Scientific Journals 29% 
 
8.0% <0.001 
News Letters  
28% 
 
14% 
 
<0.001 
Other Sources 
(i.e. doctors prescriptions) 12% 
14% <0.05 
 
Secondary study 
 
The average number of drugs prescribed per encounter (ANDPE) was 3.16 for out-patients and 
9.7 for in-patients. The average number of antibiotics prescribed per encounter (ANAPE) were 
1.1 and 2.4 for out-patients and inpatients respectively.  
 
The percentage encounter with antibiotics (PEA) was 50.3% for out-patients and 96.7% for in-
patients. Only 4.2% of in-patient antibiotic prescriptions were based on microbial sensitivity test 
results (MCST). The percent encounter with switches in antimicrobial therapy was 52.1%, whilst 
the average number of switches per encounter was 1.35. In 18.5% of the in-patient encounters, 
there was evidence of drug incompatibilities.  
 
The knowledge, attitude and practice (KAP) survey revealed that prescribers and dispensers in 
the hospital rely on different sources for their drug information needs (MIMS vs Martindale 
Extra Pharmacopoeia). None of the prescribers surveyed was able to correctly enumerate all the 
4 steps involved in the prescribing process, approximately 25% of dispensers got at least 2 steps 
correctly, and only 9.1% of the dispensers surveyed could accurately define a hospital formulary. 
The drug supply management system was also found to be inadequate. 
 
Discussion 
 
There were a number of positive findings that arose from these two studies as well as a number 
of areas of concern. Areas of concern that need to be addressed to enhance the rational use of 
medicines in in Pakistan in the future include measures to improve history taking an diagnosis in 
some provinces, enhance the prescribing of low cost generics and reducing inappropriate 
prescribing including antibiotics and potentiall polypharmacy. 
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There appeared to be adequate history taking and relevant physical examinations in 
approximately half the physicians surveyed (Table 3). However, this was significantly higher in 
the Punjab versus KPK, which suggests educational activities should be undertaken among 
physicians in the KPK region to improve history taking and examinations. 59% of physicians 
also informed their patients about their diagnosis and 76% wrote the diagnosis on the 
prescription. Again, this was significantly higher in the Punjab province (Table 3) suggesting the 
need for educational activities in the KPK region. The statistically higher occurrence of these 
four indicators in the Punjab compared with the KPK province may reflect differences in the 
communicative approaches in the two provinces. Practitioners in the Punjab typically have better 
communication and rapport with their patients, which needs to be addressed in the KPK region. 
There appeared to be limited differences in the number of tests ordered versus those required. 
This is encouraging, although there were again concerns in the KPK province (Table 3).   
 
It was also encouraging to see that disease severity and socioeconomic factors were important 
influencers of prescribing (Table 5), especially given the typical low income of most patients 
(Table 2).  
 
There appeared to be appreciable prescribing of bisphosphonates (Table 4) compared to other 
drug classes including the PPIs as well as medicines for diabetes, hypertension and 
dyslipidaemia. This included a trend in the prescribing of bisphosphonates along with vitamins, 
including vitamin D, and calcium supplements in accordance with current recommendations 
(81). This would suggest that osteoporosis is currently seen as a more serious disease than 
cardiovascular disease as there appeared to be lower use of antihypertensives and lipid-lowering 
drugs despite most hospital formularies, where they exist, not including bisphosphonates.  
However, this needs to be confirmed before any definitive statements can be made. 
 
The lack of bisphosphonates in hospital formularies means 100% patient co-payment. High 
patient co-payments can be an issue, especially with the low income level of most patients (Table 
2), similar to other publications (6, 7, 9). This resulted in the majority of prescriptions being 
below 250 Pak Rs for both regions, although there are again differences between them (Table 5). 
Increasing the availability and prescribing of low cost generics may help to address this, and 
increase the availability and utilisation of bisphosphonates.  
 
We acknowledge that we have not looked at current adherence rates with the bisphosphonates 
which, as mentioned earlier, can be a concern, augmented if co-payments are an issue. In 
addition, we did not specifically looked at the concomitant use of PPIs and bisphosphonates 
given, as mentioned, increasing concerns with the long term use of PPIs and the development of 
fractures and infections  (74, 75, 82). These areas will be the subject of future research projects 
given the growing prevalence of osteoporosis in Pakistan and the need to adequately treat these 
patients to prevent future fractures. 
 
Whilst not the principal subject of this research paper, the apparent limited prescribing of lipid 
lowering treatments in Pakistan is a concern (Table 5). This is despite non-communicable 
diseases such as diabetes being a high priority alongside communicable disease (7, 34).  A 
separate analysis has shown that the limited prescribing of lipid lowering drugs is not helped by 
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these medicines currently being unavailable in most public health care facilities (34). In addition, 
osteoporosis may currently be seen by patients as having greater importance, and hence a higher 
priority when co-payments are required. However, this is speculation at this stage. This again 
will be the subject of future research projects. 
 
There were a number of areas of concern. These include the number of medicines prescribed by 
originator (brand name) rather than generic (INN) name. This may well be enhanced by 
physicians believing generic medicines are less safe than brand name medicines (8), augmented 
by currently concerns with the low quality threshold for registration of medicines in Pakistan (9), 
and their variable availability (9), and the average number of medicines prescribed per encounter 
(Table 3) including antibiotics (second study). In addition, the lack of a formularies, the lack of 
knowledge about the prescribing process and steps involved with developing formularies (study 
2), patient demand influencing prescribing (both studies especially in the Punjab region ± Table 
6), availability of medicines at the various facilities (Table 6) as well as medical representatives 
being the key source of prescribing information especially in the KPK region (Table 7). The 
latter finding mirrors other studies which have shown the influence of medical representatives in 
Pakistan (8).  
 
The average number of drugs per prescription at 4.9 and 5.32 respectively in the Punjab and 
KPK regions (Table 3) appeared high compared with the Attock District of Pakistan at 4.1 drugs 
per prescription (4.5 private and 2.77 public) as well as the average of 2 to 3 in lower and middle 
income countries (9, 32).  This level of prescribing may not always be appropriate since 
polypharmacy, which is generally described as 5 or more medications (83-86), can cause 
problems to patients. Problems include negative health outcomes, which incorporate adverse 
drug reactions and potentially harmful drug interactions, poor adherence and geriatric 
syndromes, which include urinary incontinence, cognitive impairment and impaired balance 
leading to falls (83, 84, 87), as well as contributing to hospitalizations (88). However, we cannot 
comment further without analyzing the rationale behind the prescribing of the different 
medicines to individual patients and over time. This will also be the subject of further research, 
especially among private sector facilities where individual motivation and incentives appear 
important, including patient demands and fear of losing patients (Table 6).  
 
We believe the lack of formularies among the various facilities in Pakistan, as well as the 
variable availability of generic medicines, resulted in more than 70% drugs being prescribed by 
their originator (brand name) rather than INN name (Table 3). This may be enhanced by the 
promotional strategies of pharmaceutical companies leading to concerns with generics (8, 89, 
90), which were a major source of information regarding medicines (Table 7). In addition, brand 
name medicines may well be a potential income source for private practitioners especially with 
previous research showing that private practitioners in Pakistan are more likely to prescribe 
originator drugs, antibiotics and injectables than physicians in other countries (32).  The low 
percentage of prescriptions by their generic (INN) name adds to high cost of drugs to patients 
(91), especially as good quality generics, e.g. generic omeprazole and simvastatin, are priced as 
low as 2% to 4% of pre-patent loss prices in the Netherlands, Sweden and the UK (14, 15, 40). 
Generic prices in Pakistan can be as low as 10% to 30% of originator (brand name) prices 
especially in the public sector; however, generic prices are very variable (7, 92). Methods to 
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enhance INN prescribing include educational and other initiatives as seen in the UK (15); 
alternatively, compulsory INN prescribing as seen in Abu Dhabi and Lithuania (93, 94). 
 
Patient demand can be a concern when it comes to prescribing behaviour (Table 6), especially if 
it enhances the inappropriate prescribing of antibiotics (95-97). The considerable frequency of 
prescriptions for antibiotics in each physician: patient encounter, which is similar to other studies 
(9), the low use of microbial sensitivity test results (Study 2), coupled with patient demand 
generally for medicines (Table 6), suggests that multiple interventions will be needed among all 
key stakeholder groups in Pakistan to enhance future rational use of antibiotics.. This also applies 
to dentists in Pakistan (98). Potential strategies for antibiotics could be based on campaigns 
successfully undertaken in Europe (24, 30, 99-102). For example in France, the government 
launched a nationwide campaign to reduce the antibiotic use in the community, which reduced 
unnecessary antibiotics by 26.5% over 5 years (24). In Italy, a community-based educational 
intervention campaign including posters, brochures, and advertisements in the local media, 
coupled with a newsletter on antibiotic resistance targeting pharmacists and physicians, 
significantly improved antibiotic prescribing (100). A ten year multi-faceted programme in 
Slovenia involving physicians and the health insurance agency, and targeting both physicians 
and patients, also successfully reversed a growing trend in antibiotic prescribing (27). 
 
The last major challenge to address will be to introduce regulations that lead to active DTCs in 
all healthcare facilities. This will enhance appropriate prescribing as well as prescribers¶ and 
dispensers¶ knowledge of the prescribing process and formulary management. Alongside this, 
the development, distribution and monitoring of physician adherence to standard treatment 
guidelines for high priority disease areas (33). The WHO provides good guidance on how to 
establish DTCs (41), and the experience in Stockholm, Sweden, and other countries suggests that 
trusted physicians should be a key element in the development of formularies and prescribing 
guidance to enhance subsequent adherence (18, 19). Such activities should be undertaken 
alongside instigating continuous medical education and continuous professional development 
(CPD) for physicians surrounding an agreed list of prescribed drugs. Such activities will help 
reduce the reliance on medical representatives to provide information on medicines (Table 7). 
Concerns that pharmaceutical company activities appreciably influence prescribing behaviour, 
including the prescribing of more expensive brand medicines  (89, 95, 103-105), has  resulted in 
a number of countries introducing measures to reduce their activities alongside measures to 
enhance the rational use of medicines. This includes limiting pharmaceutical company contacts 
with physicians and gifts, with the potential for fines for inappropriate activities (106, 107). This 
provides exemplars for the authorities in Pakistan. 
 
The development of appropriate formularies and STGs should be seen as part of a long-term 
campaign in Pakistan to enhance the appropriate management of patients with chronic diseases. 
The Pakistan Medical and Dental Council, pharmacy groups, the Federal Ministry of Health and 
the provincial departments of Health should play a key role with developing these formularies, 
guidelines and indicators, to improve future patient care. Part of the rationale of involving all key 
stakeholder groups should be to ensure that all identified medicines in the formularies are 
available and affordable at each facility. These activities should improve medicine use (33) as 
this is influenced by the medicines on the formulary and their availability at each facility (Table 
6).  
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Other major areas to address including strategies to enhance the quality of locally produced 
generics at prices that enhance their affordability for all citizens in Pakistan (7). 
 
Limitations of this study include the fact that the studies were conducted in only five large cities 
in two Provinces and involved representative samples rather than the total physician population. 
However, as stated, these two Provinces comprise approximately half of the population in 
Pakistan. In addition, we believe in view of the number of physicians included in the two studies, 
coupled the total number prescriptions analysed, that the findings are robust and generalizable to 
the whole of Pakistan. We are also aware that we did not correlate diagnosis, treatment and 
outcomes in our analysis. However, Pakistan currently does not have a comprehensive drug 
utilization system that can link drug use by patients to outcomes (such as improved patient health 
and reduced hospitalizations) and link drug use and outcomes across payers (public and private) 
and across sectors (primary care, acute care and continuing care, including long-term care). This 
is an area for the future. Having said this, we believe that there were interesting findings 
emanating from this research to provide guidance to all key stakeholder groups in Pakistan to 
improve the care of patients. 
 
Conclusion 
 
The study suggests that the prescribing of bisphosphonates is common in Pakistan along with 
increased prescribing of Vitamin D, certainly compared to medicines for other NCDs such as 
cardiovascular disease and diabetes. There was also adequate history taking and examinations in 
approximately half of the physicians surveyed as well as prescribing taking into account issues 
such as disease severity and the socioeconomic status of patients, which is encouraging.  
 
However, there are concerns with the availability of bisphosphonates and other medicines to treat 
patients in high priority disease areas.  There is also a need to enhance the prescribing of generics 
versus originators as well as ensure low prices for generics to enhance access to priority 
medicines. These include generic bisphosphonates, antihypertensives and statins as well as drugs 
to treat diabetes. There is also a need to develop and instigate robust formularies in each facility 
in Pakistan alongside continuing medical educatiRQWRUHGXFHSK\VLFLDQV¶ reliance on medical 
representatives for information regarding medicines. Such activities will improve prescribers and 
dispensers knowledge of the process surrounding the generation and management of hospital 
formularies. There is also a need for educational initiatives among both patients and physicians 
to enhance the appropriate use of antibiotics given current high rates of prescribing and limited 
testing.  
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